StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Merck (MRK) announces EC Approves its KEYTRUDA in Combination with Inlyta as First-Line Treatment for Patients with Advanced RCC
September 4, 2019 6:51 AM
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)
September 4, 2019 6:45 AM